Screener / SEC EDGAR /CIK 0001906324 /10-K filed Feb 19, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Diagnostics

QuidelOrtho Corp QDEL

Compare with peers Embed
Earnings releases

Latest results release: Nov 3, 2026

8-K item 2.02, exhibit 99

What QDEL's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

In its release of Nov 3, 2026, QDEL reported −$0.78 per share under GAAP and $0.31 on its own adjusted basis.

GAAP EPS $-3.77, release Aug 5, 2025: GAAP diluted loss per share was $3.77 Adjusted EPS $0.12, release Aug 5, 2025: GAAP diluted loss per share was $3.77; adjusted diluted earnings per share (“EPS”) was $0.12 SAN DIEGO, CA August 5, 2025 — QuidelOr 2025-08 GAAP EPS $-1.92, release Feb 11, 2026: GAAP diluted loss per share was $1.92 Adjusted EPS $0.46, release Feb 11, 2026: GAAP diluted loss per share was $1.92; adjusted diluted earnings per share (“EPS”) was $0.46. 2026-02 GAAP EPS $-1.35, release May 5, 2026: GAAP diluted loss per share was $1.35 Adjusted EPS $-0.04, release May 5, 2026: GAAP diluted loss per share was $1.35; adjusted diluted loss per share was $0.04. 2026-05 GAAP EPS $-1.36, release Aug 6, 2026: GAAP diluted loss per share was $1.36 Adjusted EPS $0.13, release Aug 6, 2026: GAAP diluted loss per share was $1.36; adjusted diluted earnings per share (“EPS”) was $0.13. 2026-08 GAAP EPS $-0.78, release Nov 3, 2026: GAAP diluted loss per share was $0.78 Adjusted EPS $0.31, release Nov 3, 2026: GAAP diluted loss per share was $0.78; adjusted diluted earnings per share (“EPS”) was $0.31. 2026-11
GAAP EPSAdjusted EPS, as the company defines itThe figure on top is how far adjusted is from GAAP. Click a bar for the sentence.
The company's words, latest release
GAAP diluted loss per share was $0.78 release
GAAP diluted loss per share was $0.78; adjusted diluted earnings per share (“EPS”) was $0.31. release

What the company says its adjusted numbers leave out:

This press release contains financial measures that are considered non-GAAP financial measures under applicable rules and regulations of the Commission, including but not limited to “adjusted EBITDA,” “adjusted EBITDA margin,” “adjusted diluted EPS,” “constant currency non-respiratory revenue changes, excluding Donor Screening revenue,” “constant currency Labs revenue changes,” “constant currency Flu revenue changes,” “free cash flow,” “non-GAAP operating expenses” and other non-GAAP financial measures included in the reconciliation tables accompanying this press release. release Feb 11, 2026

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 3, 2026 · EX-99.1

QuidelOrtho Reports Third Quarter 2026 Financial Results

Open on SEC

― Growth in Labs and Immunohematology Outside of China Highlights Underlying Business Strength ―

― New Cost Transformation and Enterprise Restructuring Program Expected to Deliver Over $80 Million in Annual Savings in 2027 ―

― Updated Full-Year 2026 Financial Guidance Narrowing Prior Ranges ― November 3, 2026

— QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a leading global provider of diagnostic solutions, today announced financial results for the third quarter ended September 27, 2026.

• Total revenue was $619 m illion, a decrease of 12% both as reported and in constant currency. Excluding respiratory, China, and the U.S. Donor Screening business, total revenue grew 2% as reported and 3% in constant currency, reflecting the underlying strength of the business.

◦ Labs revenue of $353 million declined 6% both as reported and in constant currency, primarily due to lower sales in China related to recently announced changes to In Vitro Diagnostics pricing . Outside China, Labs revenue grew 3% as reported and 4% in constant currency, driven by continued strength across the business.

◦ Immunohematology revenue of $142 million was flat as reported and increased 1% in constant currency. Outside China, Immunohematology revenue g rew 2% as reported and 3% i n constant currency.

◦ Point of Care revenue of $120 million declined 27% both as reported and in constant currency due to a softer respiratory season.

• GAAP net loss was $54 million; GAAP operating loss was $8 million; adjusted EBITDA was $148 million.

• GAAP net loss margin was 8.7%; GAAP operating loss margin was 1.2%; adjusted EBITDA margin wa s 23.9% .

• GAAP diluted loss per share was $0.78; adjusted diluted earnings per share (“EPS”) was $0.31.

“The underlying performance of our Labs and Immunohematology businesses remained solid in the third quarter, supported by the strength and durability of our customer relationships and our large global installed base,” said Brian J. Blaser, President and Chief Executive Officer of QuidelOrtho. “While China and a softer respiratory season continue to pressure our results, we are taking decisive action to strengthen the Company through a new cost transformation and enterprise restructuring program. This program is designed to improve profitability and cash flow while evolving our operating model around the distinct needs of our customers and markets. We believe these actions will help mitigate near-term headwinds and position the Company for sustainable long-term growth.”

The Company has initiated a new cost transformation and enterprise restructuring program designed to further improve its cost structure and evolve its operating model around two focused businesses, Core Diagnostics and Point of Care Diagnostics. The new operating model is designed to increase customer focus, create clearer accountability for business performance, and better align technology development and investment priorities with the distinct needs of each business. The Company expects the program to deliver over $80 million in annual savings in 2027 and to record approximately $30 to $35 million in one-time restructuring charges in the fourth quarter of 2026.

Based on its current business outlook, the Company is updating its full-year financial guidance below:

Please see page 8 of the Third Quarter 2026 Financial Results presentation on the “Investor Relations” page of the Company’s website for the full list of assumptions on which the Company’s current 2026 financial guidance is based.

A reconciliation of forward-looking non-GAAP measures, including adjusted EBITDA, adjusted EBITDA margin and adjusted diluted EPS, to the most directly comparable GAAP measures is not provided because comparable GAAP measures for such measures are not reasonably accessible or reliable due to the inherent difficulty in forecasting and quantifying measures that would be necessary for such reconciliation. We are not, without unreasonable effort, able to reliably predict the impact of impairment charges and related tax benefits and other non- recurring adjustments. These items are uncertain, depend on various factors and may have a material impact on our future GAAP results. In addition, the Company believes any such reconciliation would imply a degree of precision and certainty that could be confusing to investors. See "Forward-Looking Statements" and "Non- GAAP Financial Measures."

QuidelOrtho will hold a conference call and webcast today beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the live webcast on the “Investor Relations” page of the Company’s website at https://ir.quidelortho.com/events-and-presentations . A replay of the webcast will be available shortly after the event on the Company’s website.

QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook and X.

With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are any statement contained herein that is not strictly historical, including, but not limited to, QuidelOrtho’s commercial and other strategic goals, financial guidance for 2026 and related assumptions and other future financial condition and operating results, including growth expectations and expected results of operations, financial position or cost-savings and operational improvement initiatives, including the expected results and anticipated benefits of the cost transformation and enterprise restructuring program and the timing and amount of related charges, and other future plans, objectives, strategies, expectations and intentions. Without limiting the foregoing, the words “may,” “will,” “could,” “would,” “should,” “might,” “expect,” “anticipate,” “believe,” “estimate,” “plan,” “intend,” “goal,” “project,” “strategy,” “future,” “continue,” “aim,” “strive,” “seek” or similar words, expressions or the negative of such terms or other comparable terminology are intended to identify forward-looking statements. Such statements are based on the beliefs and expectations of QuidelOrtho’s management as of the date of this press release and are subject to significant known and unknown risks and uncertainties. Actual results or outcomes may differ significantly from those set forth or implied in the forward-looking statements. The following factors, among others, could cause actual

results or outcomes to differ from those set forth or implied in the forward- looking statements: fluctuations in demand for QuidelOrtho’s non-respiratory and respiratory products; supply chain, production, logistics, distribution and labor disruptions and challenges; inability to successfully identify, consummate or realize the anticipated benefits of strategic transactions, strategic restructurings, divestitures, spin-offs or discontinuances of certain business operations, or debt financings, on the anticipated timelines, or at all; delays in the development of or failures or delays in the receipt of approvals for new or enhanced products; failure of new products and services to be commercially viable or accepted; changes in reimbursement rates for our products, including reimbursement rate reductions by the China National Health Security Administration; and other macroeconomic, geopolitical, market, business, competitive and/or regulatory factors affecting the business of QuidelOrtho generally, including those arising from the effects of announced or future or amended tariffs, trade policies, investigations, global trade relations and other tariff-related developments, as well as those discussed in QuidelOrtho’s Annual Report on Form 10-K for the fiscal year ended December 28, 2025 and subsequent reports filed with the Securities and Exchange Commission (the “Commission”), including under Part I, Item 1A, “Risk Factors” of the Form 10-K. You should not rely on forward-looking statements as predictions of future events because these statements are based on assumptions that may not come true and are speculative by their nature. All forward-looking statements are based on information currently available to QuidelOrtho and speak only as of the date of this press release. QuidelOrtho undertakes no obligation to update any of the forward-looking information or time-sensitive information included in this press release, whether as a result of new information, future events, changed expectations or otherwise, except as required by law.

This press release contains financial measures that are considered non-GAAP financial measures under applicable rules and regulations of the Commission, including but not limited to “constant currency total revenue changes,” “constant currency total revenue changes, excluding respiratory, China and the U.S. Donor Screening business,” “constant currency Labs revenue changes,” “constant currency Labs revenue changes, excluding China,” “constant currency Immunohematology revenue changes,” “constant currency Immunohematology revenue changes, excluding China,” “constant currency Point of Care revenue changes,” “adjusted EBITDA,” “adjusted EBITDA margin,” “adjusted diluted EPS,” “free cash flow” and other non-GAAP financial measures included in the reconciliation tables accompanying this press release. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). These non-GAAP financial measures eliminate impacts of certain non- cash, unusual or other items that the Company does not consider indicative of its ongoing operating performance, and the Company generally uses these non-GAAP financial measures to facilitate management’s financial and operational decision-making, including evaluation of the Company’s historical operating results and comparison to competitors’ operating results. The Company’s definitions of these non-GAAP measures may differ from similarly titled measures used by others. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting the Company’s business. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, management strongly encourages investors to review the Company’s consolidated financial statements and reports filed with the Commission in their entirety. Reconciliations of the historical non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the tables accompanying this press release.

September 27, 2026 December 28, 2025 ────────────────────────────────────────────────────────────────────────────── ASSETS Current assets: Cash and cash equivalents $ 166.4 $ 169.8 Accounts receivable, net 375.5 417.0 Inventories 642.7 577.6 Prepaid expenses and other current 241.5 250.5 assets Assets held for sale 19.9 32.4 Total current assets 1,446.0 1,447.3 Property, plant and 1,323.6 1,358.3 equipment, net Right-of-use assets 151.0 155.5 Intangible assets, net 2,628.3 2,563.8 Other assets 232.4 244.4 Total assets $ 5,781.3 $ 5,769.3 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 253.3 $ 279.4 Accrued payroll and related 76.4 120.3 expenses Income tax payable 3.3 11.5 Current portion of 424.4 178.3 borrowings Other current liabilities 309.7 376.6 Total current liabilities 1,067.1 966.1 Operating lease liabilities 146.9 154.4 Long-term borrowings 2,512.9 2,471.9 Deferred tax liabilities 121.5 90.0 Other liabilities 141.6 166.4 Total liabilities 3,990.0 3,848.8 Total stockholders’ equity 1,791.3 1,920.5 Total liabilities and stockholders’ $ 5,781.3 $ 5,769.3 equity

(a) We define free cash flow as operating cash flows, less payments for acquisitions of property, plant, equipment, investments and intangibles (“capital expenditures”) plus the proceeds from sale of property, plant and equipment (“capital disposals”).

(a) The term “constant currency” means we have translated local currency revenues for all reporting periods to U.S. dollars using currency exchange rates held constant for each period. This additional non-GAAP financial information is not meant to be considered in isolation from or as a substitute for financial information prepared in accordance with GAAP.

(a) The term “constant currency” means we have translated local currency revenues for all reporting periods to U.S. dollars using currency exchange rates held constant for each period. This additional non-GAAP financial information is not meant to be considered in isolation from or as a substitute for financial information prepared in accordance with GAAP.

Full text with the tables
                                                                                
  Exhibit 99.1                                                                  
                                                                                
                                                                                
            QuidelOrtho Reports Third Quarter 2026 Financial Results            
                                                                                
  ― Growth in Labs and Immunohematology Outside of China Highlights Underlying  
                              Business Strength ―                               
                                                                                
   ― New Cost Transformation and Enterprise Restructuring Program Expected to   
              Deliver Over $80 Million in Annual Savings in 2027 ―              
                                                                                
      ― Updated Full-Year 2026 Financial Guidance Narrowing Prior Ranges ―      
November 3, 2026
                                                                                
  SAN DIEGO, CA November 3, 2026                                                
                                                                                
— QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a
leading global provider of diagnostic solutions, today announced financial
results for the third quarter ended September 27, 2026.

Key Third Quarter 2026 Results:

(all comparisons are to the prior year period)

• Total revenue was $619 m illion, a decrease of 12% both as reported and in
constant currency. Excluding respiratory, China, and the U.S. Donor Screening
business, total revenue grew 2% as reported and 3% in constant currency,
reflecting the underlying strength of the business.

◦ Labs revenue of $353 million declined 6% both as reported and in constant
currency, primarily due to lower sales in China related to recently announced
changes to In Vitro Diagnostics pricing . Outside China, Labs revenue grew 3% as
reported and 4% in constant currency, driven by continued strength across the
business.

◦ Immunohematology revenue of $142 million was flat as reported and increased 1%
in constant currency. Outside China, Immunohematology revenue g rew 2% as
reported and 3% i n constant currency.

◦ Point of Care revenue of $120 million declined 27% both as reported and in
constant currency due to a softer respiratory season.

• GAAP net loss was $54 million; GAAP operating loss was $8 million; adjusted
EBITDA was $148 million.

• GAAP net loss margin was 8.7%; GAAP operating loss margin was 1.2%; adjusted
EBITDA margin wa s 23.9% .

• GAAP diluted loss per share was $0.78; adjusted diluted earnings per share
(“EPS”) was $0.31.

• Operating cash flow was $20 million; free cash flow was $0.3 million.

“The underlying performance of our Labs and Immunohematology businesses remained
solid in the third quarter, supported by the strength and durability of our
customer relationships and our large global installed base,” said Brian J.
Blaser, President and Chief Executive Officer of QuidelOrtho. “While China and a
softer respiratory season continue to pressure our results, we are taking
decisive action to strengthen the Company through a new cost transformation and
enterprise restructuring program. This program is designed to improve
profitability and cash flow while evolving our operating model around the
distinct needs of our customers and markets. We believe these actions will help
mitigate near-term headwinds and position the Company for sustainable long-term
growth.”
                                                                                
  Cost Transformation and Restructuring Program                                 
                                                                                
The Company has initiated a new cost transformation and enterprise restructuring
program designed to further improve its cost structure and evolve its operating
model around two focused businesses, Core Diagnostics and Point of Care
Diagnostics. The new operating model is designed to increase customer focus,
create clearer accountability for business performance, and better align
technology development and investment priorities with the distinct needs of each
business. The Company expects the program to deliver over $80 million in annual
savings in 2027 and to record approximately $30 to $35 million in one-time
restructuring charges in the fourth quarter of 2026.
                                                                                
  Full-year 2026 Financial Guidance                                             
                                                                                
Based on its current business outlook, the Company is updating its full-year
financial guidance below:
                                                                                
  Full-year 2026 Financial      As of 11/3/2026          As of 8/6/2026         
  Guidance                                                                      
  Total revenues (reported)     $2.52 - $2.54 billion    $2.52 - $2.60 billion  
  Adjusted EBITDA               $540 - $545 million      $540 - $560 million    
  Adjusted EBITDA margin        ~21%                     21% - 22%              
  Adjusted diluted EPS          $0.65 - $0.70            $0.65 - $0.90          
                                                                                
Please see page 8 of the Third Quarter 2026 Financial Results presentation on
the “Investor Relations” page of the Company’s website for the full list of
assumptions on which the Company’s current 2026 financial guidance is based.

A reconciliation of forward-looking non-GAAP measures, including adjusted
EBITDA, adjusted EBITDA margin and adjusted diluted EPS, to the most directly
comparable GAAP measures is not provided because comparable GAAP measures for
such measures are not reasonably accessible or reliable due to the inherent
difficulty in forecasting and quantifying measures that would be necessary for
such reconciliation. We are not, without unreasonable effort, able to reliably
predict the impact of impairment charges and related tax benefits and other non-
recurring adjustments. These items are uncertain, depend on various factors and
may have a material impact on our future GAAP results. In addition, the Company
believes any such reconciliation would imply a degree of precision and certainty
that could be confusing to investors. See "Forward-Looking Statements" and "Non-
GAAP Financial Measures."
                                                                                
  Conference Call Information                                                   
                                                                                
QuidelOrtho will hold a conference call and webcast today beginning at 2:00 p.m.
PT / 5:00 p.m. ET to discuss its financial results. Interested parties can
access the live webcast on the “Investor Relations” page of the Company’s
website at https://ir.quidelortho.com/events-and-presentations . A replay of the
webcast will be available shortly after the event on the Company’s website.

QuidelOrtho is dedicated to advancing diagnostics to power a healthier future.
For more information, please visit quidelortho.com and follow QuidelOrtho on
LinkedIn, Facebook and X.
                                                                                
  About QuidelOrtho Corporation                                                 
                                                                                
With expertise spanning clinical chemistry, immunoassay, immunohematology and
molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global
provider of diagnostic solutions, dedicated to advancing fast, accurate and
reliable results that help improve patient outcomes – from the point of care to
hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works
with healthcare providers to advance diagnostics that connect insights with
solutions, defining a clearer path for informed decisions and better care.
                                                                                
  Forward-Looking Statements                                                    
                                                                                
This press release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995. These statements are any
statement contained herein that is not strictly historical, including, but not
limited to, QuidelOrtho’s commercial and other strategic goals, financial
guidance for 2026 and related assumptions and other future financial condition
and operating results, including growth expectations and expected results of
operations, financial position or cost-savings and operational improvement
initiatives, including the expected results and anticipated benefits of the cost
transformation and enterprise restructuring program and the timing and amount of
related charges, and other future plans, objectives, strategies, expectations
and intentions. Without limiting the foregoing, the words “may,” “will,”
“could,” “would,” “should,” “might,” “expect,” “anticipate,” “believe,”
“estimate,” “plan,” “intend,” “goal,” “project,” “strategy,” “future,”
“continue,” “aim,” “strive,” “seek” or similar words, expressions or the
negative of such terms or other comparable terminology are intended to identify
forward-looking statements. Such statements are based on the beliefs and
expectations of QuidelOrtho’s management as of the date of this press release
and are subject to significant known and unknown risks and uncertainties. Actual
results or outcomes may differ significantly from those set forth or implied in
the forward-looking statements. The following factors, among others, could cause
actual

results or outcomes to differ from those set forth or implied in the forward-
looking statements: fluctuations in demand for QuidelOrtho’s non-respiratory and
respiratory products; supply chain, production, logistics, distribution and
labor disruptions and challenges; inability to successfully identify, consummate
or realize the anticipated benefits of strategic transactions, strategic
restructurings, divestitures, spin-offs or discontinuances of certain business
operations, or debt financings, on the anticipated timelines, or at all; delays
in the development of or failures or delays in the receipt of approvals for new
or enhanced products; failure of new products and services to be commercially
viable or accepted; changes in reimbursement rates for our products, including
reimbursement rate reductions by the China National Health Security
Administration; and other macroeconomic, geopolitical, market, business,
competitive and/or regulatory factors affecting the business of QuidelOrtho
generally, including those arising from the effects of announced or future or
amended tariffs, trade policies, investigations, global trade relations and
other tariff-related developments, as well as those discussed in QuidelOrtho’s
Annual Report on Form 10-K for the fiscal year ended December 28, 2025 and
subsequent reports filed with the Securities and Exchange Commission (the
“Commission”), including under Part I, Item 1A, “Risk Factors” of the Form 10-K.
You should not rely on forward-looking statements as predictions of future
events because these statements are based on assumptions that may not come true
and are speculative by their nature. All forward-looking statements are based on
information currently available to QuidelOrtho and speak only as of the date of
this press release. QuidelOrtho undertakes no obligation to update any of the
forward-looking information or time-sensitive information included in this press
release, whether as a result of new information, future events, changed
expectations or otherwise, except as required by law.
                                                                                
  Non-GAAP Financial Measures                                                   
                                                                                
This press release contains financial measures that are considered non-GAAP
financial measures under applicable rules and regulations of the Commission,
including but not limited to “constant currency total revenue changes,”
“constant currency total revenue changes, excluding respiratory, China and the
U.S. Donor Screening business,” “constant currency Labs revenue changes,”
“constant currency Labs revenue changes, excluding China,” “constant currency
Immunohematology revenue changes,” “constant currency Immunohematology revenue
changes, excluding China,” “constant currency Point of Care revenue changes,”
“adjusted EBITDA,” “adjusted EBITDA margin,” “adjusted diluted EPS,” “free cash
flow” and other non-GAAP financial measures included in the reconciliation
tables accompanying this press release. These non-GAAP financial measures should
be considered supplemental to, and not a substitute for, financial information
prepared in accordance with U.S. generally accepted accounting principles
(“GAAP”). These non-GAAP financial measures eliminate impacts of certain non-
cash, unusual or other items that the Company does not consider indicative of
its ongoing operating performance, and the Company generally uses these non-GAAP
financial measures to facilitate management’s financial and operational
decision-making, including evaluation of the Company’s historical operating
results and comparison to competitors’ operating results. The Company’s
definitions of these non-GAAP measures may differ from similarly titled measures
used by others. These non-GAAP financial measures reflect an additional way of
viewing aspects of the Company’s operations that, when viewed with GAAP results
and the reconciliations to corresponding GAAP financial measures, may provide a
more complete understanding of factors and trends affecting the Company’s
business. Because non-GAAP financial measures exclude the effect of items that
will increase or decrease the Company’s reported results of operations,
management strongly encourages investors to review the Company’s consolidated
financial statements and reports filed with the Commission in their entirety.
Reconciliations of the historical non-GAAP financial measures to the most
directly comparable GAAP financial measures are included in the tables
accompanying this press release.

Investor Contact:

Sanjeev Sharma

Vice President, Investor Relations

[email protected]

Media Contact:

Stephanie Kleewein

Senior Corporate Communications and PR Manager

[email protected]
                                                                                
                                  QuidelOrtho                                   
                                                                                
                        Consolidated Statements of Loss                         
                                                                                
                                  (Unaudited)                                   
                                                                                
                      (In millions, except per share data)                      
                                                                                
            Three    Septem…       Septem…    Nine      Septem…                 
            Months       27,           28,    Months        27,       Septemb…  
            Ended       2026          2025    Ended        2026       28, 2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Total     $          618.9    $    699.9    $         1,869.6    $   2,006.6  
  reven…                                                                        
  Cost                                                                          
  of                                                                            
  sales,                                                                        
  exclu…               329.3         364.3              1,043.3        1,052.8  
  amort…                                                                        
  of                                                                            
  intan…                                                                        
  Selli…                                                                        
  marke…               182.7         186.9                571.7          551.9  
  and                                                                           
  admin…                                                                        
  Resea…                                                                        
  and                   42.5          41.5                136.1          140.4  
  devel…                                                                        
  Amort…                                                                        
  of                    50.8          47.7                146.6          143.6  
  intan…                                                                        
  assets                                                                        
  Restr…                                                                        
  integ…                                                                        
  and                    7.1          39.6                 18.0          234.6  
  other                                                                         
  charg…                                                                        
  Goodw…                                                                        
  impai…                   —         700.7                    —          700.7  
  charge                                                                        
  Asset                                                                         
  impai…                12.5           9.7                 12.5            9.7  
  charge                                                                        
  Other                                                                         
  opera…                 1.5          14.3                  2.5           25.8  
  expen…                                                                        
  Opera…                -7.5        -704.8                -61.1         -852.9  
  loss                                                                          
  Inter…                                                                        
  expen…                55.4          46.1                161.2          126.6  
  net                                                                           
  Loss                                                                          
  on                                                                            
  extin…                   —           5.1                    —            5.1  
  of                                                                            
  debt                                                                          
  Other                                                                         
  expen…                   —           0.9                  1.3           10.7  
  net                                                                           
  Loss                                                                          
  before               -62.9        -756.9               -223.6         -995.3  
  income                                                                        
  taxes                                                                         
  (Bene…                                                                        
  from)                                                                         
  provi…                -9.1         -23.9                 14.9            5.8  
  for                                                                           
  income                                                                        
  taxes                                                                         
  Net       $          -53.8    $   -733.0    $          -238.5    $  -1,001.1  
  loss                                                                          
  Basic                                                                         
  loss      $          -0.78    $   -10.78    $           -3.49    $    -14.79  
  per                                                                           
  share                                                                         
  Dilut…                                                                        
  loss      $          -0.78    $   -10.78    $           -3.49    $    -14.79  
  per                                                                           
  share                                                                         
  Weigh…                                                                        
  shares                                                                        
  outst…                68.7          68.0                 68.4           67.7  
  -                                                                             
  basic                                                                         
  Weigh…                                                                        
  shares                                                                        
  outst…                68.7          68.0                 68.4           67.7  
  -                                                                             
  dilut…                                                                        
                                                                                
                                                                                
                                  QuidelOrtho                                   
                                                                                
                     Condensed Consolidated Balance Sheets                      
                                                                                
                                  (Unaudited)                                   
                                                                                
                                 (In millions)                                  
                                                                                
                                    September 27, 2026       December 28, 2025  
 ────────────────────────────────────────────────────────────────────────────── 
  ASSETS                                                                        
  Current assets:                                                               
  Cash and cash equivalents      $               166.4    $              169.8  
  Accounts receivable, net                       375.5                   417.0  
  Inventories                                    642.7                   577.6  
  Prepaid expenses and other                                                    
  current                                        241.5                   250.5  
  assets                                                                        
  Assets held for sale                            19.9                    32.4  
  Total current assets                         1,446.0                 1,447.3  
  Property, plant and                          1,323.6                 1,358.3  
  equipment, net                                                                
  Right-of-use assets                            151.0                   155.5  
  Intangible assets, net                       2,628.3                 2,563.8  
  Other assets                                   232.4                   244.4  
  Total assets                   $             5,781.3    $            5,769.3  
  LIABILITIES AND                                                               
  STOCKHOLDERS’ EQUITY                                                          
  Current liabilities:                                                          
  Accounts payable               $               253.3    $              279.4  
  Accrued payroll and related                     76.4                   120.3  
  expenses                                                                      
  Income tax payable                               3.3                    11.5  
  Current portion of                             424.4                   178.3  
  borrowings                                                                    
  Other current liabilities                      309.7                   376.6  
  Total current liabilities                    1,067.1                   966.1  
  Operating lease liabilities                    146.9                   154.4  
  Long-term borrowings                         2,512.9                 2,471.9  
  Deferred tax liabilities                       121.5                    90.0  
  Other liabilities                              141.6                   166.4  
  Total liabilities                            3,990.0                 3,848.8  
  Total stockholders’ equity                   1,791.3                 1,920.5  
  Total liabilities and                                                         
  stockholders’                  $             5,781.3    $            5,769.3  
  equity                                                                        
                                                                                
                                                                                
                                  QuidelOrtho                                   
                                                                                
                Condensed Consolidated Statements of Cash Flows                 
                                                                                
                                  (Unaudited)                                   
                                                                                
                                 (In millions)                                  
                                                                                
           Three   Septe…       Septem…           Nine    Septem…       Septe…  
           Months     27,           28,           Months      27,          28,  
           Ended     2026          2025           Ended      2026         2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Cash                                                                          
  prov…                                                                         
  by                                                                            
  (used    $         19.6    $    -45.5           $        -124.0    $   -26.7  
  for)                                                                          
  oper…                                                                         
  acti…                                                                         
  Cash                                                                          
  used                                                                          
  for               -20.9         -53.9                    -162.2       -143.1  
  inve…                                                                         
  acti…                                                                         
  Cash                                                                          
  prov…                                                                         
  by                 44.1          46.0                     282.3        166.9  
  fina…                                                                         
  acti…                                                                         
  Effe…                                                                         
  of                                                                            
  exch…               0.2          -0.2                       0.5          2.5  
  rates                                                                         
  on                                                                            
  cash                                                                          
  Net                                                                           
  incr…                                                                         
  (dec…                                                                         
  in                                                                            
  cash,              43.0         -53.6                      -3.4         -0.4  
  cash                                                                          
  equi…                                                                         
  and                                                                           
  rest…                                                                         
  cash                                                                          
  Cash,                                                                         
  cash                                                                          
  equi…                                                                         
  and                                                                           
  rest…             123.4                151.7              169.8         98.5  
  cash                                                                          
  at                                                                            
  begi…                                                                         
  of                                                                            
  peri…                                                                         
  Cash,                                                                         
  cash                                                                          
  equi…                                                                         
  and                                                                           
  rest…    $        166.4    $     98.1           $         166.4    $    98.1  
  cash                                                                          
  at                                                                            
  end                                                                           
  of                                                                            
  peri…                                                                         
  Free                                                                          
  Cash                                                                          
  Flow…                                                                         
  Cash                                                                          
  prov…                                                                         
  by                                                                            
  (used    $         19.6    $    -45.5           $        -124.0    $   -26.7  
  for)                                                                          
  oper…                                                                         
  acti…                                                                         
  Less:                                                                         
  Acqu…                                                                         
  of                                                                            
  prop…                                                                         
  plan…                                                                         
  equi…             -20.4         -49.2                     -80.5       -143.7  
  inve…                                                                         
  and                                                                           
  inta…                                                                         
  (cap…                                                                         
  expe…                                                                         
  Plus:                                                                         
  Proc…                                                                         
  from                                                                          
  sale                                                                          
  of                                                                            
  prop…               1.1             —                       1.7          0.8  
  plant                                                                         
  and                                                                           
  equi…                                                                         
  (cap…                                                                         
  disp…                                                                         
  Free                                                                          
  Cash     $          0.3    $    -94.7           $        -202.8    $  -169.6  
  Flow                                                                          
  (non…                                                                         
                                                                                
(a) We define free cash flow as operating cash flows, less payments for
acquisitions of property, plant, equipment, investments and intangibles
(“capital expenditures”) plus the proceeds from sale of property, plant and
equipment (“capital disposals”).
                                                                                
                                  QuidelOrtho                                   
                                                                                
     Reconciliation of Non-GAAP Financial Information - Adjusted Net Income     
                                                                                
                (In millions, except per share data; unaudited)                 
                                                                                
       T…  S…                S…             N…  S…                Se…           
       M…  2…       D…       2…       D…    M…  2…       D…       28,       D…  
       E…  2…       E…       2…       E…    E…  2…       E…       20…       E…  
 ────────────────────────────────────────────────────────────────────────────── 
  …    $   -…    $  -…    $  -…    $  -…    $   -…    $  -…    $  -1…    $  -…  
  …                                                                             
  …                                                                             
  …                                                                             
  …        5…                4…                 1…                14…           
  …                                                                             
  …                                                                             
  …                                                                             
  …        7…                3…                 1…                23…           
  …                                                                             
  …                                                                             
  …                                                                             
  …         —                7…                  —                70…           
  …                                                                             
  …                                                                             
  …        1…                9…                 1…                9.7           
  …                                                                             
  …                                                                             
  …                                                                             
  …         —                5…                  —                5.1           
  …                                                                             
  …                                                                             
  …         —                9…                  —                9.4           
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        9…                7…                 2…                19…           
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        3…                 —                 1…                  —           
  …                                                                             
  …                                                                             
  …         —                 —                 3…                  —           
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        3…                5…                 9…                15…           
  …                                                                             
  …                                                                             
  …                                                                             
  …        2…                1…                 6…                2.5           
  …                                                                             
  …                                                                             
  …                                                                             
  …        0…                0…                 1…                0.5           
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …         —                0…                 9…                -0…           
  …                                                                             
  …                                                                             
  …                                                                             
  …        0…                 —                 0…                  —           
  …                                                                             
  …                                                                             
  …        2…                2…                 1…                4.6           
  …                                                                             
  …                                                                             
  …                                                                             
  …        -…                -…                 4…                -3…           
  …                                                                             
  …                                                                             
  …                                                                             
  …    $   2…    $  0…    $  5…    $  0…    $   2…    $  0…    $  11…    $  1…  
  …                                                                             
  …                                                                             
  …                                                                             
  …                 6…                6…                 6…                 6…  
  -                                                                             
  …                                                                             
                                                                                
                                                                                
                                  QuidelOrtho                                   
                                                                                
       Reconciliation of Non-GAAP Financial Information - Adjusted EBITDA       
                                                                                
                            (In millions, unaudited)                            
                                                                                
           Three  Septe…          Sept…       Nine    Sept…          Septe…     
           Mont…     27,            28,       Months    27,             28,     
           Ended    2026           2025       Ended    2026            2025     
 ────────────────────────────────────────────────────────────────────────────── 
  Net      $       -53.8       $  -733…       $       -238…       $  -1,00…     
  loss                                                                          
  Depr…                                                                         
  and              119.6          112.1               349.2           329.5     
  amor…                                                                         
  Inte…                                                                         
  expe…             55.4           46.1               161.2           126.6     
  net                                                                           
  (Ben…                                                                         
  from)                                                                         
  prov…             -9.1          -23.9                14.9             5.8     
  for                                                                           
  inco…                                                                         
  taxes                                                                         
  Rest…                                                                         
  inte…                                                                         
  and                7.1           39.6                18.0           234.6     
  other                                                                         
  char…                                                                         
  Good…                                                                         
  impa…                —          700.7                   —           700.7     
  char…                                                                         
  Asset                                                                         
  impa…             12.5            9.7                12.5             9.7     
  char…                                                                         
  Loss                                                                          
  on                                                                            
  exti…                —            5.1                   —             5.1     
  of                                                                            
  debt                                                                          
  Legal                —            9.4                   —             9.4     
  accr…                                                                         
  Amor…                                                                         
  of                                                                            
  defe…                                                                         
  cloud              9.1            7.9                26.3            19.0     
  comp…                                                                         
  impl…                                                                         
  costs                                                                         
  Empl…                                                                         
  comp…              3.7              —                13.7               —     
  char…                                                                         
  Tax                                                                           
  inde…                —              —                 3.3               —     
  expe…                                                                         
  EU                                                                            
  medi…                                                                         
  devi…              0.2            0.2                 1.6             0.5     
  regu…                                                                         
  tran…                                                                         
  costs                                                                         
  Loss                                                                          
  (gai…                —            0.6                 9.0            -0.7     
  on                                                                            
  inve…                                                                         
  Cred…                                                                         
  Agre…              0.5              —                 0.5               —     
  amen…                                                                         
  fees                                                                          
  Other              2.8            2.6                14.3             4.6     
  adju…                                                                         
  Adju…    $       148.0       $  177.1       $       386.0       $   443.7     
  EBIT…                                                                         
  Total    $       618.9       $  699.9       $       1,86…       $  2,006…     
  reve…                                                                         
  Adju…                                                                         
  EBIT…             23.9  %        25.3  %             20.6  %         22.1  %  
  marg…                                                                         
                                                                                
                                                                                
                                  QuidelOrtho                                   
                                                                                
          Reconciliation of Non-GAAP Financial Information - Revenues           
                                                                                
                            (In millions, unaudited)                            
                                                                                
          Three  Sept…       Septe…                                             
          Mont…    27,          28,          %         Curre…         Cons…     
          Ended   2026         2025      Chan…         Impact         Curr…     
 ────────────────────────────────────────────────────────────────────────────── 
  Labs    $      353.2    $   373.8       -5.5  %         0.4  %       -5.9  %  
  Imm…           142.0        142.0          —  %        -0.9  %        0.9  %  
  Don…             1.7         14.7      -88.4  %           —  %      -88.4  %  
  Scr…                                                                          
  Poi…                                                                          
  of             119.6        164.6      -27.3  %        -0.1  %      -27.2  %  
  Care                                                                          
  Mol…             2.4          4.8      -50.0  %        -0.7  %      -49.3  %  
  Dia…                                                                          
  Tot…    $      618.9    $   699.9      -11.6  %           —  %      -11.6  %  
  rev…                                                                          
                                                                                
                                                                                
          Three  Sept…       Septe…                                             
          Mont…    27,          28,          %         Curre…         Cons…     
          Ended   2026         2025      Chan…         Impact         Curr…     
 ────────────────────────────────────────────────────────────────────────────── 
  Tot…    $      618.9    $   699.9      -11.6  %           —  %      -11.6  %  
  rev…                                                                          
  Res…            68.8        112.3      -38.7  %           —  %      -38.7  %  
  Chi…                                                                          
  exc…            48.4         84.4      -42.7  %         3.2  %      -45.9  %  
  res…                                                                          
  U.S.                                                                          
  Don…             0.5         13.1      -96.0  %           —  %      -96.0  %  
  Scr…                                                                          
  Tot…                                                                          
  rev…                                                                          
  exc…                                                                          
  res…                                                                          
  Chi…    $      501.2    $   490.1        2.3  %        -0.7  %        3.0  %  
  and                                                                           
  U.S.                                                                          
  Don…                                                                          
  Scr…                                                                          
                                                                                
                                                                                
          Three  Sept…       Septe…                                             
          Mont…    27,          28,          %         Curre…         Cons…     
          Ended   2026         2025      Chan…         Impact         Curr…     
 ────────────────────────────────────────────────────────────────────────────── 
  Labs    $      353.2    $   373.8       -5.5  %         0.4  %       -5.9  %  
  Chi…            36.9         67.7      -45.5  %         3.2  %      -48.7  %  
  Labs                                                                          
  Tot…                                                                          
  Labs                                                                          
  rev…    $      316.3    $   306.1        3.3  %        -0.5  %        3.8  %  
  exc…                                                                          
  Chi…                                                                          
                                                                                
(a) The term “constant currency” means we have translated local currency
revenues for all reporting periods to U.S. dollars using currency exchange rates
held constant for each period. This additional non-GAAP financial information is
not meant to be considered in isolation from or as a substitute for financial
information prepared in accordance with GAAP.
                                                                                
          Three  Sept…       Septe…                                             
          Mont…    27,          28,          %         Curre…         Cons…     
          Ended   2026         2025      Chan…         Impact         Curr…     
 ────────────────────────────────────────────────────────────────────────────── 
  Imm…    $      142.0    $   142.0          —  %        -0.9  %        0.9  %  
  Chi…             8.0         10.2      -21.6  %         4.1  %      -25.7  %  
  Imm…                                                                          
  Tot…                                                                          
  Imm…                                                                          
  rev…    $      134.0    $   131.8        1.7  %        -1.3  %        3.0  %  
  exc…                                                                          
  Chi…                                                                          
                                                                                
(a) The term “constant currency” means we have translated local currency
revenues for all reporting periods to U.S. dollars using currency exchange rates
held constant for each period. This additional non-GAAP financial information is
not meant to be considered in isolation from or as a substitute for financial
information prepared in accordance with GAAP.

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/QDEL/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.